資源描述：
《肺癌靶向治療進展-2012(周彩存).pdf》由會員上傳分享，免費在線閱讀，更多相關(guān)內(nèi)容在行業(yè)資料-天天文庫。
1、肺癌靶向治療進展－2012同濟大學(xué)附屬上海市肺科醫(yī)院腫瘤科周彩存TargetingtheEpidermalGrowthFactorReceptor?EGFR突變：EGFRTKI一線首選?西妥昔單抗在晚期NSCLC治療中地位？SELECT?第二代EGFRTKI有效LUX-Lung3PF-299[TITLE]Supplementaryanalysis:influenceofEGFRTKIandchemotherapyonOSEventsMedian1.0nn(%)(months)95%CIReceivedchemoonly*2117(81)11.707.29–22.870.8R
2、eceivedEGFRTKIonly?3322(67)20.6716.62–28.32ReceivedEGFRTKIandchemo§9450(53)30.3925.99–NR0.60.4OSprobabilityPatientsreceivingEGFRTKIandchemovspatientsreceivingchemoonlyp=0.00010.2PatientsreceivingEGFRTKIonlyvspatientsreceivingchemoonlyp=0.057Log-rankpvalue<0.000100510152025303540Patientsatr
3、iskTime(months)Patientsreceivingchemoonly*21171286430PatientsreceivingEGFRTKIonly?33322724171270PatientsreceivingEGFRTKIandchemo§949489806860286*Chemoonly,noEGFRTKI:patientsfromtheGCarmwhohadnofurthertreatment(n=16)orfurtherchemotherapy(n=5)?EGFRTKIonly,nochemo:patientsfromtheerlotinibarmw
4、hoarestillontreatment(n=7),hadnofurthertreatment(n=25)andwhowerere-challenged(n=1)§EGFRTKIandchemo:patientsfromtheerlotinibarmwhoswitchedtochemo(n=43),patientsfromtheGCarmwhoswitchedtoerlotinibinanyline(n=51)[TITLE]Primaryendpoint:PFSIndependentreview?allrandomizedpatients1.0AfatinibCis/pe
5、mn=230n=115PFSevent,n(%)152(66)69(60)0.8MedianPFS(months)11.16.9Hazardratio0.58(0.43–0.78)0.6ival(probability)(95%confidenceinterval)P=0.000447%0.40.222%Progression-freesurv0.00369121518212427Progression-freesurvival(months)NumberatriskAfatinib2301801511207750311030Cis/Pem1157241211173200Y
6、angJC,etal.PFS:Commonmutations(Del19/L858R)Independentreview–patientswithDel19/L858R(n=308)1.0AfatinibCis/pemn=204n=1040.8PFSevent,n(%)130(64)61(59)MedianPFS(months)13.66.9Hazardratio0.47(0.34–0.65)0.6(95%confidenceinterval)P<0.00010.40.2Progression-freesurvival(probability)0.0036912151821
7、2427Progression-freesurvival(months)NumberatriskAfatinib2041691431157549301030Cis/Pem104623517962200YangJC,etal.[TITLE][TITLE]First-linedacomitinib(PF-00299804),anirreversiblepan-HERtyrosinekinaseinhibitorforpatientswithEGFR-mutantlungcancerMGKris,Mok,SHIOu,et
